PRVB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2023 @ 16:00):

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases...

Stats
Today's Volume	9.12M
Average Volume	2.84M
Market Cap	2.38B
EPS	$0 ( 2024-03-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.43
ATR14	$0.594 (2.38%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Sessa Capital (master), L.p.	Sell	15 567 497	Common Stock
2023-04-27	Wysenski Nancy	Sell	128 981	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	22 200	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	23 000	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	33 000	Option to Purchase Common Stock

INSIDER POWER
-62.81
Last 100 transactions
Buy: 11 373 023 \| Sell: 48 540 195

Volume Correlation

Long: 0.34 (neutral)

Short: 0.37 (neutral)

Signal:(80.187) Neutral

Provention Bio Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Provention Bio Inc Correlation - Currency/Commodity

0.75
( moderate )

0.59
( weak )

-0.82
( strong negative )

0.78
( moderate )

0.00
( neutral )

-0.11
( neutral )

Provention Bio Inc Financials

Annual	2022
Revenue:	$12.90M
Gross Profit:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2022
Revenue:	$12.90M
Gross Profit:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2021
Revenue:	$1.40M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.810

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.880

Financial Reports:

No articles found.

Provention Bio Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Provention Bio Inc

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.